Logo image of STTK

SHATTUCK LABS INC (STTK) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:STTK - US82024L1035 - Common Stock

3.5 USD
+0.15 (+4.48%)
Last: 12/29/2025, 8:20:52 PM
3.599 USD
+0.1 (+2.83%)
Pre-Market: 12/30/2025, 8:17:03 AM
Fundamental Rating

3

Taking everything into account, STTK scores 3 out of 10 in our fundamental rating. STTK was compared to 530 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for STTK as it has an excellent financial health rating, but there are worries on the profitability. STTK does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

STTK had negative earnings in the past year.
STTK had a negative operating cash flow in the past year.
In the past 5 years STTK always reported negative net income.
In the past 5 years STTK always reported negative operating cash flow.
STTK Yearly Net Income VS EBIT VS OCF VS FCFSTTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of STTK (-55.03%) is comparable to the rest of the industry.
With a decent Return On Equity value of -59.22%, STTK is doing good in the industry, outperforming 61.32% of the companies in the same industry.
Industry RankSector Rank
ROA -55.03%
ROE -59.22%
ROIC N/A
ROA(3y)-62.4%
ROA(5y)-42.55%
ROE(3y)-70.96%
ROE(5y)-48.25%
ROIC(3y)N/A
ROIC(5y)N/A
STTK Yearly ROA, ROE, ROICSTTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

STTK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STTK Yearly Profit, Operating, Gross MarginsSTTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

8

2. Health

2.1 Basic Checks

STTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STTK has been increased compared to 1 year ago.
The number of shares outstanding for STTK has been increased compared to 5 years ago.
STTK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
STTK Yearly Shares OutstandingSTTK Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
STTK Yearly Total Debt VS Total AssetsSTTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 12.02 indicates that STTK is not in any danger for bankruptcy at the moment.
STTK has a Altman-Z score of 12.02. This is amongst the best in the industry. STTK outperforms 83.96% of its industry peers.
STTK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.02
ROIC/WACCN/A
WACC8.78%
STTK Yearly LT Debt VS Equity VS FCFSTTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

STTK has a Current Ratio of 17.00. This indicates that STTK is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 17.00, STTK belongs to the best of the industry, outperforming 93.58% of the companies in the same industry.
STTK has a Quick Ratio of 17.00. This indicates that STTK is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 17.00, STTK belongs to the top of the industry, outperforming 93.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17
Quick Ratio 17
STTK Yearly Current Assets VS Current LiabilitesSTTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.33% over the past year.
The Revenue for STTK has decreased by -84.46% in the past year. This is quite bad
STTK shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.37% yearly.
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.58%
Revenue 1Y (TTM)-84.46%
Revenue growth 3Y-42.45%
Revenue growth 5Y-10.37%
Sales Q2Q%-66.63%

3.2 Future

STTK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.59% yearly.
STTK is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y46.95%
EPS Next 2Y27.95%
EPS Next 3Y18.83%
EPS Next 5Y10.59%
Revenue Next Year-81.56%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
STTK Yearly Revenue VS EstimatesSTTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2031 100M 200M 300M 400M
STTK Yearly EPS VS EstimatesSTTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for STTK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STTK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STTK Price Earnings VS Forward Price EarningsSTTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STTK Per share dataSTTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as STTK's earnings are expected to grow with 18.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.95%
EPS Next 3Y18.83%

0

5. Dividend

5.1 Amount

No dividends for STTK!.
Industry RankSector Rank
Dividend Yield 0%

SHATTUCK LABS INC

NASDAQ:STTK (12/29/2025, 8:20:52 PM)

Premarket: 3.599 +0.1 (+2.83%)

3.5

+0.15 (+4.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners44.32%
Inst Owner Change27.17%
Ins Owners1.7%
Ins Owner Change0.02%
Market Cap221.48M
Revenue(TTM)1.00M
Net Income(TTM)-55.22M
Analysts78.33
Price Target4.08 (16.57%)
Short Float %1.49%
Short Ratio2.77
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.82%
Min EPS beat(2)3.96%
Max EPS beat(2)7.68%
EPS beat(4)3
Avg EPS beat(4)0.99%
Min EPS beat(4)-13.57%
Max EPS beat(4)7.68%
EPS beat(8)7
Avg EPS beat(8)9.36%
EPS beat(12)10
Avg EPS beat(12)7.28%
EPS beat(16)12
Avg EPS beat(16)13.92%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)33.33%
PT rev (3m)73.41%
EPS NQ rev (1m)-5.99%
EPS NQ rev (3m)4.96%
EPS NY rev (1m)1.75%
EPS NY rev (3m)6.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 221.48
P/FCF N/A
P/OCF N/A
P/B 2.38
P/tB 2.38
EV/EBITDA N/A
EPS(TTM)-1.02
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0.02
BVpS1.47
TBVpS1.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -55.03%
ROE -59.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.4%
ROA(5y)-42.55%
ROE(3y)-70.96%
ROE(5y)-48.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.91%
Cap/Sales 7.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17
Quick Ratio 17
Altman-Z 12.02
F-Score4
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)129.93%
Cap/Depr(5y)216.43%
Cap/Sales(3y)603.92%
Cap/Sales(5y)369.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.58%
EPS Next Y46.95%
EPS Next 2Y27.95%
EPS Next 3Y18.83%
EPS Next 5Y10.59%
Revenue 1Y (TTM)-84.46%
Revenue growth 3Y-42.45%
Revenue growth 5Y-10.37%
Sales Q2Q%-66.63%
Revenue Next Year-81.56%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y27.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.43%
EBIT Next 3Y9.68%
EBIT Next 5Y-5.63%
FCF growth 1Y42.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.33%
OCF growth 3YN/A
OCF growth 5YN/A

SHATTUCK LABS INC / STTK FAQ

What is the fundamental rating for STTK stock?

ChartMill assigns a fundamental rating of 3 / 10 to STTK.


What is the valuation status for STTK stock?

ChartMill assigns a valuation rating of 0 / 10 to SHATTUCK LABS INC (STTK). This can be considered as Overvalued.


Can you provide the profitability details for SHATTUCK LABS INC?

SHATTUCK LABS INC (STTK) has a profitability rating of 1 / 10.


What is the financial health of SHATTUCK LABS INC (STTK) stock?

The financial health rating of SHATTUCK LABS INC (STTK) is 8 / 10.